Dova Pharmaceuticals, Inc. (DOVA) financial statements (2022 and earlier)

Company profile

Business Address 240 LEIGH FARM ROAD
DURHAM, NC 27707
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments104,56694,846
Cash and cash equivalents104,56694,846
Receivables612 
Inventory, net of allowances, customer advances and progress billings4,390 
Inventory4,390 
Prepaid expense6271,471
Other undisclosed current assets1,612 
Total current assets:111,80796,317
Noncurrent Assets
Property, plant and equipment36262
Total noncurrent assets:36262
TOTAL ASSETS:112,16996,379
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,7954,788
Accounts payable7811,263
Accrued liabilities11,9352,520
Interest and dividends payable791,005
Debt6,66730,212
Due to related parties3597
Other undisclosed current liabilities 100
Total current liabilities:19,49735,197
Noncurrent Liabilities
Long-term debt and lease obligation13,941 
Long-term debt, excluding current maturities13,941 
Liabilities, other than long-term debt2,373 
Contract with customer, liability2,373
Total noncurrent liabilities:16,314 
Total liabilities:35,81135,197
Stockholders' equity
Stockholders' equity attributable to parent76,35861,182
Common stock2826
Additional paid in capital205,757118,301
Accumulated deficit(129,427)(57,145)
Total stockholders' equity:76,35861,182
TOTAL LIABILITIES AND EQUITY:112,16996,379

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
Revenues10,355 
Cost of revenue
(Cost of Goods and Services Sold)
(1,180) 
Gross profit:9,175 
Operating expenses(81,405)(29,209)
Other undisclosed operating income1,180 
Operating loss:(71,050)(29,209)
Nonoperating income
(Other Nonoperating income)
644486
Interest and debt expense(1,876)(1,231)
Loss before gain (loss) on sale of properties:(72,282)(29,954)
Other undisclosed net loss (1)
Net loss available to common stockholders, diluted:(72,282)(29,955)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
Net loss:(72,282)(29,955)
Comprehensive loss, net of tax, attributable to parent:(72,282)(29,955)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: